XML 67 R47.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue - Incyte Corporation (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 24 Months Ended 87 Months Ended
Aug. 31, 2024
USD ($)
Oct. 31, 2017
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2019
performanceObligation
Collaboration and Other Agreements [Line Items]                  
Revenues       $ 149,962 $ 58,749 $ 151,941      
Incyte MGA012 Agreement | Incyte Corporation (Incyte)                  
Collaboration and Other Agreements [Line Items]                  
Non-refundable upfront payment     $ 150,000            
Amounts recognized               $ 215,000  
Number of performance obligations | performanceObligation                 2
Transaction price   $ 154,000              
Clinical trial activities selling price amount             $ 4,000    
Minimum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)                  
Collaboration and Other Agreements [Line Items]                  
Potential proceeds from royalties percent   15.00%              
Maximum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)                  
Collaboration and Other Agreements [Line Items]                  
Potential development and regulatory milestone payments   $ 210,000              
Potential commercial milestone payments   $ 330,000              
Potential proceeds from royalties percent   24.00%              
Revenues From License Agreements | Incyte MGA012 Agreement | Incyte Corporation (Incyte)                  
Collaboration and Other Agreements [Line Items]                  
Revenues $ 100,000 $ 150,000   100,600 15,000 30,000      
Revenues From License Agreements | Incyte MGA012 Supply Agreement | Incyte Corporation (Incyte)                  
Collaboration and Other Agreements [Line Items]                  
Revenues       200 1,900 700      
Revenues From License Agreements | Incyte MGA012 Clinical Services | Incyte Corporation (Incyte)                  
Collaboration and Other Agreements [Line Items]                  
Revenues       $ 1,800 $ 4,200 $ 300